1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cardiovascular conditions
  5. Lipid disorders

Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia

Technology appraisal guidance [TA733] Published: 06 October 2021

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

History

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) PDF 143 KB 06 October 2021  
  • Final appraisal document (updated after appeal period) PDF 326 KB 06 October 2021  
  • Register of interests PDF 158 KB 06 October 2021  

Final draft guidance

  • Final draft guidance  
  • Final appraisal document PDF 307 KB 01 September 2021  
  • Committee papers PDF 9.94 MB 01 September 2021  
  • Public committee slides PDF 1.34 MB 01 September 2021  

Invitation to participate

  • NICE's response to comments on the draft scope and provisional stakeholder list PDF 115 KB 26 August 2020  
  • Final scope PDF 90 KB 26 August 2020  
  • Final stakeholder list PDF 171 KB 26 August 2020  
  • Equality impact assessment (Scoping) PDF 125 KB 26 August 2020  

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

  • Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators  
  • Draft scope post referral PDF 211 KB 13 July 2020  
  • Draft matrix post referral PDF 170 KB 13 July 2020